Basic Information
Levemir
Regulatory Information
EMEA/H/C/000528
Authorised
June 1, 2004
February 26, 2004
29
July 13, 2021
Company Information
Denmark
Novo Allé DK-2880 Bagsværd
Novo Nordisk A/S
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Levemir. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Levemir.